Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

1.02USD
8:00pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.02
Open
$1.04
Day's High
$1.05
Day's Low
$1.00
Volume
22,857
Avg. Vol
46,877
52-wk High
$7.85
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

Cellect Biotechnology Announces Pricing Of $6.5 Mln Public Offering
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES PRICING OF $6.5 MILLION PUBLIC OFFERING.CELLECT BIOTECHNOLOGY LTD - EACH UNIT WILL BE SOLD AT $1.50 PER UNIT AND EACH PRE-FUNDED UNIT WILL BE SOLD AT $1.49 PER PRE-FUNDED UNIT.CELLECT BIOTECHNOLOGY - PRICING OF PUBLIC OFFERING OF 1.89 MILLION UNITS.CELLECT BIOTECHNOLOGY - PRE-FUNDED WARRANTS WILL BE EXERCISABLE AT ANY TIME AFTER DATE OF ISSUANCE UPON PAYMENT OF EXERCISE PRICE OF $0.01 PER ADS.  Full Article

Cellect Biotechnology reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD QTRLY LOSS PER SHARE $0.014.CELLECT BIOTECHNOLOGY - CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $6.45 MILLION AS OF SEPT 30 VERSUS $8.26 MILLION ON JUNE 30.  Full Article

Cellect Biotechnology Q1 Loss Per Ads $0.16
Thursday, 17 May 2018 

May 17 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY LTD PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - QTRLY BASIC AND DILUTED LOSS PER ADS $0.16.CELLECT BIOTECHNOLOGY LTD - CASH AND CASH EQUIVALENTS, MARKETABLE SECURITIES AND SHORT-TERM DEPOSITS TOTALED $9.8 MILLION AS OF MARCH 31, 2018.  Full Article

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

No consensus analysis data available.